NCT07098338 (LIBRA) is a Phase 2 clinical trial of Rilvegostomig in Non-Small Cell Lung Cancer, sponsored by AstraZeneca.

Who is sponsoring NCT07098338?

NCT07098338 is sponsored by AstraZeneca.

What drugs are being tested in NCT07098338?

Interventions in NCT07098338: Rilvegostomig, Ramucirumab, Dato-DXd.

What condition does NCT07098338 study?

NCT07098338 studies Non-Small Cell Lung Cancer.

Is NCT07098338 still recruiting?

NCT07098338 is currently recruiting now. Last updated 5 February 2026.

Last reviewed 2026-02-05 · How we verify

NCT07098338: LIBRA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

Recruiting now Phase 2 Last updated 5 February 2026

What this trial tests

Phase 2 trial testing Rilvegostomig in Non-Small Cell Lung Cancer in 278 participants. Currently enrolling.

Timeline

7 August 2025

Primary endpoint
6 April 2029

6 April 2029

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	278
Start date	7 August 2025
Primary completion	6 April 2029
Estimated completion	6 April 2029
Sites	63 locations across Japan, Taiwan, South Korea, Canada, Thailand, Australia, China, Singapore

Drugs / interventions tested

Rilvegostomig — full drug profile →
Ramucirumab (RAMUCIRUMAB) — full drug profile →
Dato-DXd — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

AstraZeneca — full company profile →

Who can join

18 and older, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Rilvegostomig

Trials testing the same drug.

NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07221253 — A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Bili · Phase 3 · recruiting
NCT06996782 — A Platform Study in Non-Small Cell Lung Cancer (NSCLC) · Phase 1, PHASE2 · recruiting
NCT07069712 — A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gast · Phase 2 · recruiting
NCT06921785 — Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of · Phase 3 · recruiting

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07098338 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 5 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07098338.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing